UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB
                                   (Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934 FOR THE PERIOD ENDED      September 30, 2002
                                       OR
[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD From _____________ to __________________
..

                        Commission File Number 333-60362

                             NEURO BIOSCIENCE, INC.
                             ----------------------
             (Exact name of registrant as specified in its charter)
                        Filed Effective November 14, 2002

                 Utah                                      87-0670014
                 ----                                      ----------
     (State or other jurisdiction of                    (I.R.S. Employer
     incorporation or organization)                     Identification No.)

                           1251 Avenue of the Americas
                               New York, NY 10020
                           ---------------------------
                    (Address of principal executive officers)

                                 (212)  591-0256
                                 ---------------
               (Registrant's telephone number, including area code)

 Mortgage Professionals Lead Source, Inc., 959 East Akers Way, Sandy, UT   84094
 -------------------------------------------------------------------------------
   (Former name, former address and former fiscal year, if changed since last
                                     report)

Indicate by check mark whether the registrant (l) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter periods that the registrant was
required to file such reports),    X Yes       No; and (2) has been subject to
such filing requirements for the past 90 days:   X Yes       No

                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant has filed all documents and
reports required to be filed by Sections 12, 13, or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by the court. Yes  No    Not Applicable

                      APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practical date.

Common Stock: 619,300 shares issued as of November 10, 2002.  No Par Value.
Authorized - 50,000,000 common voting shares.  The company has only one class of
shares.


                                        1


                                      INDEX

                             Neuro Bioscience, Inc.
                KNOWN AS MORTGAGE PROFESSIONALS LEAD SOURCE, INC.
                    FOR THE QUARTER ENDING SEPTEMBER 30, 2002
  NO ACCOUNTING CONTAINED HEREIN REELECTS THE ACQUISITION OF NEURO BIOSCIENCE,
  INC. WHICH BECAME EFFECTIVE NOVEMBER 14, 2002 AND WHICH WILL BE SUBSEQUENTLY
                                    REPORTED.

Part I.  Financial Information

     Item 1.   Financial Statements

                 Condensed Balance Sheets - September 30, 2002 (Unaudited).

                 Condensed Statements of Operations (Unaudited) - For the
                  Nine Months Ended September 30, 2002 and For the Period
                  February 16, 2001 (Date of Inception) Through September 30,
                  2001 and for the Three Months Ended September 30, 2002 and
                  2001 and For the Period from February 16, 2001 (Date of
                  Inception) through September 30, 2002.

                 Condensed Statements of Cash Flows (Unaudited) - For Nine
                  Months Ended September 30, 2002 and For the Period February
                  16, 2001 (Date of Inception) through September 30, 2001 and
                  2002.

                 Notes to Condensed Financial Statements (Unaudited)

     Item 2.   Management's Discussion and Analysis of Financial
                Condition and Results of Operations

     Item 3.   Controls and Procedures

Part II.  Other Information

     Item 1.   Legal Proceedings

     Item 2.   Changes in Securities and Use of Proceeds

     Item 4.   Submission of Matters to a Vote of Security Holders

     Item 6.   Exhibits and Reports on Form 8-K

Signatures

<PAGE>

                         Part I - Financial Information

Item 1.  Financial Statements

                    MORTGAGE PROFESSIONALS LEAD SOURCE, INC.
                        (A Development Stage Enterprise)
                            CONDENSED BALANCE SHEETS
                                   (UNAUDITED)

                                                     September 30, December 31,
                                                          2002         2001
                                                       ----------   ----------
                                     ASSETS
Current Assets
  Cash                                                 $   28,450   $   99,910
                                                       ----------   ----------

Total Assets                                           $   28,450   $   99,910
                                                       ==========   ==========

                 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current Liabilities
  Accounts payable                                     $    6,991   $   23,104
                                                       ----------   ----------
  Total Current Liabilities                                 6,991       23,104
                                                       ----------   ----------

Stockholders' Equity (Deficit)
  Common stock , no par value; 50,000,000
   shares authorized;  619,300 shares
   issued and outstanding                                 126,592      126,592
  Deficit accumulated during the
   development stage                                     (105,133)     (49,786)
                                                       ----------   ----------
    Total Stockholders' Equity (Deficit)                   21,459       76,806
                                                       ----------   ----------

Total Liabilities and Stockholders'
 Equity (Deficit)                                      $   28,450   $   99,910
                                                       ==========   ==========

         The accompanying notes are an integral part of these
                   condensed financial statements.

                                2


                    MORTGAGE PROFESSIONALS LEAD SOURCE, INC.
                        (A Development Stage Enterprise)
                       CONDENSED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)
<TABLE>
<CAPTION>
                                         For the Period                            For the Period
                                          February 16,                              February 16,
                               For the    2001 (Date of                             2001 (Date of
                             Nine Months   Inception)       For the Three Months      Inception)
                                Ended        Through         Ended September 30,       Through
                             September 30, September 30,  -------------------------  September 30,
                                 2002          2001          2002          2001          2002
                              -----------   -----------   -----------   -----------   -----------
<S>                          <C>           <C>           <C>           <C>           <C>
Revenue                       $       300   $         -   $         -   $         -   $       300

General and administrative
  expenses                         55,647        26,553        25,690         1,130       105,433
                              -----------   -----------   -----------   -----------   -----------
Net Loss                      $   (55,347)  $   (26,553)  $   (25,690)  $    (1,130)  $  (105,133)
                              ===========   ===========   ===========   ===========   ===========
Basic and Diluted Loss
 Per Share                    $     (0.09)  $     (0.05)  $     (0.04)  $     (0.00)
                              ===========   ===========   ===========   ===========
Weighted Average Number
 of Shares Outstanding            619,000       510,000       619,000       510,000
                              ===========   ===========   ===========   ===========
</TABLE>

         The accompanying notes are an integral part of these
                   condensed financial statements.

                                3


                    MORTGAGE PROFESSIONALS LEAD SOURCE, INC.
                      (A Company in the Development Stage)
                        CONDENSED STAEMENTS OF CASH FLOWS
                                   (UNAUDITED)



                                                            For the Period
                                                        From February 16, 2001
                                                For the   (Date of Inception)
                                                 Nine          Through
                                             Months Ended --------------------
                                              September   September  September
                                               30, 2002    30, 2001   30, 2002
                                              ---------   ---------  ----------
Cash Flows From Operating Activities
  Net loss                                    $ (55,347)  $ (26,553) $ (105,133)
  Stock issued for services                           -      25,000      25,000
  Changes in current assets and liabilities:
     Prepaid expense                                  -      (4,775)          -
     Accounts payable                           (16,113)        400       6,991
                                              ---------   ---------  ----------
      Net Cash Used in Operating
      Activities                                (71,460)     (5,928)    (73,142)
                                              ---------   ---------  ----------
      Net Cash Used in Investing
      Activities                                      -           -           -
                                              ---------   ---------  ----------

Cash Flows From Financing Activities
  Proceeds from issuance of common stock              -       5,000     114,300
  Offering costs on initial public                    -      (1m300)    (27,708)
  Cash received on receivable
   from shareholders                                  -      15,000      15,000
                                              ---------   ---------  ----------
      Net Cash Provided by Financing
      Activities                                      -      18,700     101,592
                                              ---------   ---------  ----------

Net Increase (Decrease) in Cash                 (71,460)     12,772      28,450

Cash at Beginning of Period                      99,910           -           -
                                              ---------   ---------  ----------

Cash at End of Period                         $  28,450   $  12,772  $   28,450
                                              =========   =========  ==========
Non-Cash Investing and Financing Activities:
Common stock issued for receivable
 from shareholders                            $       -   $  15,000  $   15,000
Accrual of deferred offering costs            $       -   $  26,408  $   26,408


         The accompanying notes are an integral part of these
                   condensed financial statements.

                                4


                    MORTGAGE PROFESSIONALS LEAD SOURCE, INC.
                      (A Company in the Development Stage)
                     NOTES TO CONDENSED FINANCIAL STATEMENTS
                                   (UNAUDITED)


NOTE 1 -  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Interim   Financial   Statements-The  accompanying  financial   statements   are
unaudited.  In  the  opinion  of  management, all necessary  adjustments  (which
include only normal recurring adjustments) have been made to present fairly  the
financial  position,  results  of operations and  cash  flows  for  the  periods
presented.  Certain information and disclosures normally included  in  financial
statements prepared in accordance with accounting principles generally  accepted
in  the United States of America have been condensed or omitted. It is suggested
that  these  condensed  financial statements be read  in  conjunction  with  the
Company's  financial statements and notes thereto included in  the  Form  10-KSB
dated  March  25,  2002.  The results of operations for the  nine  months  ended
September 30, 2002 are not necessarily indicative of the operating results to be
expected for the full year ending December 31, 2002.

Business Condition - The accompanying financial statements have been prepared on
a  going  concern basis, which contemplates the realization of  assets  and  the
satisfaction of liabilities in the normal course of business. During the  period
from  February 16, 2001 (date of inception) through June 30, 2002,  the  Company
incurred  a  net  loss and accumulated deficit of $105,133 and  used  cash  from
operations  of $73,142. These factors, among others, indicate that  the  Company
may  be  unable  to  continue  as a going concern.  The  accompanying  financial
statements  do not include any adjustments relating to the carrying  amount  and
classification   of  recorded  assets  or  the  amount  and  classification   of
liabilities that might be necessary should the Company be unable to continue  as
a  going  concern.  As  of  December 31, 2001, the Company  had  received  gross
proceeds  of  $109,300 from its initial registered public offering. The  Company
incurred  costs totaling $27,708 in conjunction with this offering.   Subsequent
to  September 30, 2002 (see Note 3), the Company entered into a merger agreement
with another company.  There are no assurances that the reorganized company will
be profitable.

NOTE 2 - CONSULTING AGREEMENT

In  July  2002,  the  Company entered into an agreement with  Belsen  Getty  for
consulting  services  related  to merger and acquisition  possibilities,  future
capital  funding, and related financial matters.  The Company paid Belsen  Getty
$25,000  and principle shareholders agreed to transfer 329,000 of their existing
capital stock to Belsen Getty.

NOTE 3 - LETTER OF INTENT AND SUBSEQUENT STOCK EXCHANGE AGREEMENT

On  September 26, 2002, the Company entered into a Letter of Intent  with  Neuro
Bioscience,  Inc.  ("Neuro"), by which the Company would fully  acquire  Neuro's
stock  in  exchange for the issuance of 9,000,000 restricted  shares  of  common
stock  of  the Company.  On November 12, 2002, the Company consummated  a  Share
Exchange  through  a special shareholder meeting in which the ownership  of  the
Company  changed  by  a majority share acquisition of Neuro.   After  the  Share
Exchange,  Neuro  owns approximately 93.4% of the total issued  and  outstanding
shares  of the Company.  Also in connection with the transaction, management  of
the  Company changed through the nomination and election of a new board proposed
by Neuro.


                                        5


Item 2.  Management's Discussion and Analysis of Financial Condition and Results
of Operations

Forward-Looking Information

Certain  statements  in this Section and elsewhere in this report  are  forward-
looking  in nature and relate to trends and events that may affect the Company's
future  financial  position and operating results.   Such  statements  are  made
pursuant  to  the  safe  harbor provisions of the Private Securities  Litigation
Reform Act of 1995.  The terms "expect,""anticipate,""intend," and "project" and
similar   words   or  expressions  are  intended  to  identify   forward-looking
statements.   These statements speak only as of the date of  this  report.   The
statements  are  based  on current expectations, are inherently  uncertain,  are
subject  to  risks,  and  should be viewed with  caution.   Actual  results  and
experience may differ materially from the forward-looking statements as a result
of  many factors, including changes in economic conditions in the markets served
by the company, increasing competition, fluctuations in raw materials and energy
prices,  and  other unanticipated events and conditions.  It is not possible  to
foresee or identify all such factors.  The company makes no commitment to update
any forward-looking statement or to disclose any facts, events, or circumstances
after  the  date  hereof  that may affect the accuracy  of  any  forward-looking
statement.

Results of Operations

Mortgage  Professionals Lead Source, Inc. ("MPLS") was incorporated in  Utah  on
February16,  2001  and  has been involved primarily to this  point  in  start-up
operations  including incorporation, initial organization and an initial  public
offering  ("IPO") of its shares and start-up marketing operations.  The offering
became effective with the Securities and Exchange Commission (SEC) on August 16,
2001  and  in the State of Utah on such date by coordination.  The offering  was
closed on December 5, 2001 after raising $109,300 in gross proceeds.

As  previously  reported on Form 8-K, the Company consummated a  Share  Exchange
through  a  Special  Shareholder  Meeting on November  12,  2002  in  which  the
ownership  of the Company changed by a majority share acquisition of a privately
held Company known as Neuro Bioscience, Inc., a Delaware Corporation having  its
principal  place  of  business  in  New York  City,  NY  in  exchange  to  NBI's
shareholders of most of the Company's stock.

As  reported,  this  exchange  resulted in Neuro Bioscience,  Inc.  being  fully
acquired by Mortgage Professionals Lead Source, Inc. which then changed its name
of  record by the filing of Articles of Share Exchange in the State of  Utah  to
Neuro  Bioscience,  Inc. as of November 14, 2002.  As a  result  of  such  Share
Exchange the following significant events have occurred in the Company:

      (1)   The  Company  has changed its business purpose  from  attempting  to
provide mortgage refinancing services to the research, development and potential
marketing  of experimental new pharmaceutical products through its  fully  owned
and sole operating subsidiary, Neuro Bioscience, Inc.


                                        5


      (2)   Management  of  the Company has changed through the  nomination  and
election of a new Board proposed by Neuro Bioscience, Inc. as more fully set-out
in the 8-K filings by the Company.

     (3)  The Company has changed its business location from Utah to 1251 Avenue
of the Americas, New York, NY 10020.

      (4)   Essentially all of the remaining liquid assets of the  Company  were
employed  and  expended  to  pay for costs and services  related  to  the  Share
Exchange Agreement.

      (5)   No  value  determination of the intangible  assets,  primarily  five
development stage pharmaceutical products owned by Neuro Bioscience,  Inc.,  has
been  made  at  this time.  The Company would intend to file  a  subsequent  8-K
report  employing  consolidated financial statements for the  combined  entities
within a sixty day period from the filing of its last 8-K on November 14, 2002.

      (6)   The  principal  ownership of the Company now is  comprised  of  five
British  based business entities who have previously been associated with  Neuro
Bioscience, Inc.  and who collectively own approximately 93.4% of the issued and
outstanding  stock  of  the  Company pursuant to the  Share  Exchange.     These
matters  were  more  fully detailed in the concurrently  filed  8-K  Report  and
documents.

      (7)   It is not certain what impact, if any, the reorganization will  have
upon the limited trading market of the Company, but the Company will most likely
obtain a new trading symbol, CUSIP number and federal tax number.

AS  A  RESULT  OF THE FOREGOING TRANSACTIONS, EACH PERSON REVIEWING THIS  REPORT
SHOULD FULLY UNDERSTAND THAT THE ACCOUNTING AND INFORMATION SUPPLIED AS PART  OF
THIS REPORT IS FOR THE PERIOD PRIOR TO THIS REORGANIZATION THROUGH SEPTEMBER 30,
2002  AND  WILL  LIKELY  BE  SUBSTANTIALLY  CHANGED  AND  UPDATED  DUE  TO   THE
REORGANIZATION  TO  BE  REPORTED PURSUANT TO  THE FUTURE ANTICIPATED  FILING  OF
CONSOLIDATED FINANCIALS AS DESCRIBED ABOVE.

The  accumulated  deficit for MPLS during the development stage  resulting  from
general  and administrative and expenses was $105,133 as of September 30,  2002.
There  remained  approximately $28,450 of net proceeds from the offering  as  of
September  30,  2002.     However, as noted above, substantially  all  of  these
proceeds have been subsequently expended related to the Share Exchange.

The  Company  has  abandoned  implementation of its initial  marketing  plan  to
attempt  to secure refinancing commitments from home owners and small businesses
on existing mortgage loans through mass marketing techniques.


                                        6


The  overhead  for  the  Company was approximately $4,600  per  month  including
estimated expenses for reporting and operating as a public trading company.   It
is  intended  that  overhead will substantially change as the Company  moves  to
implement  future operations from its new base of operations in  New  York,  New
York.   No  assurance is made or implied the Company can continue to  exist,  or
that  it will be successful in its new business opportunities.  To date, neither
MPLS or Neuro Bioscience has realized any revenues or income.


Liquidity and Sources of Capital

The  Company  will seek subsequent private placement financing funds,  loans  or
other  means  to  continue its operations, though there can be no  assurance  or
warranty  that  any  such funds will be available.   The target  range  of  this
funding is $5 to $10 million over the next six to twelve months.

Plan of Operations

The  company  is presently modifying its business plan to attempt  to  integrate
active  development,  testing and potential marketing of  its  five  development
stage  pharmaceutical products.  Neuro is engaged in the early development stage
of  five  pharmaceutical  products which are intended  to  treat  various  human
central  nervous  system  disorders and symptoms related  to  diseases  such  as
Parkinsons  Disease, Alzheimers and other central nervous system disorders.   It
should be noted that these drugs are in the early development stages and that no
approval by the FDA or other drug regulatory authority has been obtained for the
marketing or distribution of these drugs and no assurance or warranty that  such
drugs  will ultimately be approved, marketed or be efficacious  can be  made  or
given by the Company.

Item 3.  Controls and Procedures

     (a)  The Company maintains controls and procedures designed to ensure that
          information required to be disclosed in the reports that the Company
          files or submits under the Securities Exchange Act of 1934 is
          recorded, processed, summarized and reported within the time periods
          specified in the rules and forms of the Securities and Exchange
          Commission.  Based upon their evaluation of those controls and
          procedures performed with 90 days of the filing date of this report,
          the chief executive officer and the principal financial officer of the
          Company concluded that the Company's disclosure controls and
          procedures were adequate.

     (b)  Changes in internal controls.  The Company made no significant
          changes in its internal controls or in other factors that could
          significantly affect these controls subsequent to the date of
          the evaluation of those controls by the chief executive officer
          and principal financial officer.

                                        7


                           Part II - Other Information

Item 1.  Legal Proceedings

The Company is not presently engaged in any legal proceedings, nor does it know
of any claims for or against the company by any party.


Item 2.  Changes in Securities and Use of Proceeds

The company has not had any change in its securities since its last report
filing on Form SB-1.

In accordance with SEC Rule 463 the company reports the use of proceeds to date
from its initial public offering "IPO" completed on December 5, 2001:

     1.   Gross proceeds sold - $109,300.

     2.   Accrued offering related costs including printing, accounting, legal
          and related filing fees - $27,708.

     3.   Amount expended to September 30, 2002 on marketing and operations -
          $53,142.

     4.   Approximate amounts expended related to Share Exchange - $6,600.

     5.   Approximate amount expended subsequent to September 30, 2002 unrelated
          to stock exchange.

     6.   Approximate balance remaining - $10,500*
          *To be substantially expended pursuant to accrued but currently unpaid
          costs primarily related to SEC filings and share exchange.


Item 4.  Submission of Matters to a Vote of Security Holders

During the present quarter there has been no matter submitted to security
holders for a vote.  Subsequent to the date of this Report, the Company held a
Special Shareholders Meeting on November 12, 2002 to approve the terms of the
Share Exchange including the change of name as generally described above.  These
changes were approved by majority vote, and the new Board was also elected by
majority vote as reported on the Form 8-K.


Item 6.  Exhibits and Reports on Form 8-K:

The Company has filed two reports on Form 8-K subsequent to September 30, 2002
but prior to filing this report:

                                        8

                 (i)  An 8-K was filed October  2, 2002 describing the Letter
            of Intent and proposed terms of Share Exchange with Neuro
            Bioscience, Inc.

                 (ii) A subsequent 8-K was filed November 14, 2002 describing
            the definitive terms of the Share Exchange, name change and
            shareholder vote.


EXHIBITS:
                 99.1 Certification under Section 90-6 of the Sarbanes-Oxley
            Act (18 U.S.C. SECTION 1350)



                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant
has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.

REGISTRANT:  MORTGAGE PROFESSIONAL LEAD SOURCE, INC.


Date:  November 14, 2002      By:  /s/  Gregory Willits
                             _________________________________
                             Mr. Gregory Willits
                             President - (Resigning)


Date:  November 14, 2002     By:   /s/  Michael J. Christensen
                             _________________________________
                             Mr. Michael J. Christensen
                             Chief Financial and Accounting Officer
                             (Resigning)


                                        9








                                  EXHIBIT 99.1


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of Mortgage Professional Lead Source,
Inc. now known as Neuro Bioscience, Inc.  (the "Company") on Form 10-QSB for the
period ending September 30, 2002, as filed with the Securities and Exchange
Commission on the date hereof (the "Report"), we, Mr. Gregory Willits, President
and Mr. Michael J. Christensen, Chief Financial and Accounting Officer of the
Company, certify to the best of our knowledge, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:

     (1)  The report fully complies with the requirements of section 13 (a) or
15 (d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.


                             /s/  Gregory Willits
                             ___________________________________
                             Mr. Gregory Willits
                             President


                             Michael J. Christensen
                             ___________________________________
                             Mr. Michael J. Christensen
                             Chief Financial Officer




                                        10


                                  Attachment A

                                  CERTIFICATION


I,  Gregory  Willits,  President,  of Mortgage Professionals  Lead  Source,  Inc
certify that:

      (1)   I  have  reviewed this quarterly report on Form 10-QSB  of  Mortgage
Professionals Lead Source, Inc.;

      (2)   Based  on my knowledge, this quarterly report does not  contain  any
untrue  statement of a material fact necessary to make the statements  made,  in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this quarterly report;

      (3)   Based on my knowledge, the financial statements, and other financial
information  included in this quarterly report fairly present  in  all  material
respects  the financial condition, results of operations and cash flows  of  the
registrant as of, and for, the periods presented in this quarterly report;

      (4)  The registrant's other certifying officers and I are responsible  for
establishing and maintaining disclosure controls and procedures (as  defined  in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

          (a)  designed  such disclosure controls and procedures to ensure  that
               material  information relating to the registrant,  including  its
               consolidated  subsidiaries, is made known to us by others  within
               those  entities,  particularly during the period  in  which  this
               quarterly report is being prepared;

          (b)  evaluated   the  effectiveness  of  the  registrant's  disclosure
               controls and procedures as of a date within 90 days prior to  the
               filing date of this quarterly report (the "Evaluation Date'); and

          (c)  presented  in  this  quarterly report our conclusions  about  the
               effectiveness of the disclosure controls and procedures based  on
               our evaluation as of the Evaluation Date;

     (5)  The registrant's other certifying officers and I have disclosed, based
on  our  most  recent  evaluation, to the registrant's auditors  and  the  audit
committee  of  registrant's  board  of  directors  (or  persons  performing  the
equivalent function):

          (a)  all  significant  deficiencies in  the  design  or  operation  of
               internal  controls which could adversely affect the  registrant's
               ability  to record, process, summarize and report financial  data
               and  have  identified for the registrant's auditors any  material
               weaknesses in internal controls; and

                                          11


          (b)  any  fraud, whether or not material, that involves management  or
               other  employees who have a significant role in the  registrant's
               internal controls; and

      (6)   The  registrant's other certifying officers and I have indicated  in
this  quarterly report whether or not there were significant changes in internal
controls  or in other factors that could significantly affect internal  controls
subsequent  to the date of our most recent evaluation, including any  corrective
actions with regard to significant deficiencies and material weaknesses.

               DATE:       November 14, 2002

                             /s/  Gregory Willits
                              __________________________________
                              Gregory Willits
                              President

                                  Attachment A



                                        12


                                  CERTIFICATION


I,  Michael  J.  Christensen, Chief Financial Officer, of Mortgage Professionals
Lead Source, Inc certify that:

      (1)   I  have  reviewed this quarterly report on Form 10-QSB  of  Mortgage
Professionals Lead Source, Inc.;

      (2)   Based  on my knowledge, this quarterly report does not  contain  any
untrue  statement of a material fact necessary to make the statements  made,  in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this quarterly report;

      (3)   Based on my knowledge, the financial statements, and other financial
information  included in this quarterly report fairly present  in  all  material
respects  the financial condition, results of operations and cash flows  of  the
registrant as of, and for, the periods presented in this quarterly report;

      (4)  The registrant's other certifying officers and I are responsible  for
establishing and maintaining disclosure controls and procedures (as  defined  in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

          (a)  designed  such disclosure controls and procedures to ensure  that
               material  information relating to the registrant,  including  its
               consolidated  subsidiaries, is made known to us by others  within
               those  entities,  particularly during the period  in  which  this
               quarterly report is being prepared;

          (b)  evaluated   the  effectiveness  of  the  registrant's  disclosure
               controls and procedures as of a date within 90 days prior to  the
               filing date of this quarterly report (the "Evaluation Date'); and

          (c)  presented  in  this  quarterly report our conclusions  about  the
               effectiveness of the disclosure controls and procedures based  on
               our evaluation as of the Evaluation Date;

     (5)  The registrant's other certifying officers and I have disclosed, based
on  our  most  recent  evaluation, to the registrant's auditors  and  the  audit
committee  of  registrant's  board  of  directors  (or  persons  performing  the
equivalent function):


                                        13


          (a)  all  significant  deficiencies in  the  design  or  operation  of
               internal  controls which could adversely affect the  registrant's
               ability  to record, process, summarize and report financial  data
               and  have  identified for the registrant's auditors any  material
               weaknesses in internal controls; and

          (b)  any  fraud, whether or not material, that involves management  or
               other  employees who have a significant role in the  registrant's
               internal controls; and

      (6)   The  registrant's other certifying officers and I have indicated  in
this  quarterly report whether or not there were significant changes in internal
controls  or in other factors that could significantly affect internal  controls
subsequent  to the date of our most recent evaluation, including any  corrective
actions with regard to significant deficiencies and material weaknesses.

               DATE:  November 14, 2002

                             Michael J. Christensen
                              _______________________
                              Michael J. Christensen
                              Chief Financial Officer


                                        14